LEXINGTON, Mass.--(BUSINESS WIRE)--April 19, 2006--Predix Pharmaceuticals, which recently announced a definitive agreement to merge with EPIX Pharmaceuticals (NASDAQ: EPIX - News), today announced that it has completed a Phase Ib clinical trial to study the pharmacodynamics and tolerability of PRX-08066 in 15 adults conditioned to exercise at high altitudes, with elevated pulmonary artery pressures induced by low oxygen levels (hypoxia). Preliminary results from this trial indicate that treatment with PRX-08066 resulted in a statistically significant reduction in systolic pulmonary blood pressure during exercise hypoxia.
